Cellphire Therapeutics, Inc.
Company profile
Primary focus
Developing next-generation platelet-derived therapeutics to address critical bleeding issues in trauma, surgery, and critical care settings.
Why it’s included
The company develops and manufactures freeze-dried platelet-derived hemostatic products such as Thrombosomes and CLPH-211, explicitly designed for hemorrhagic shock and critical bleeding with extended shelf life and rapid reconstitution, directly matching the topic's requirements.
Relevant capabilities
- Lyophilization of platelets to produce a long‑shelf‑life hemostatic
- Cryopreservation of platelets using DMSO for extended frozen storage
- Apheresis platelet pooling and donor processing (leukoreduction, irradiation)
- cGMP / cleanroom manufacturing for cellular biologics (ISO 7 suites)
- Analytical testing and lot release (sterility, endotoxin, potency, identity)
Commercial sectorShelf-Stable and Extended-Storage Blood Components
Technology classesCryopreserved platelets (DMSO, -80°C), Platelet-derived hemostatic particles, Freeze-dried platelets (trehalose-based), Pathogen reduction for blood components, Blood bags and storage containers
Relevant commercial products
- Lyophilized platelet‑derived hemostatic (freeze‑dried activated platelets)
- DMSO‑stabilized cryopreserved platelet suspension (frozen activated platelets)
Relevant patents
4 families, 5 publications- Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use US-8486617-B2
- Platelet derivative compositions, and methods of making and using such compositions US-12702682-B2
- Methods using freeze-dried platelet derivative compositions for restoring hemostasis in a subject US-12295972-B2
- Freeze-dried platelets, method of making and method of use as a diagnostic agent US-8097403-B2